

Organic & Biomolecular Chemistry

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

First Total Synthesis of (+)-Goniothalesacetate and Syntheses of (+)-Altholactone, (+)-Gonioheptolide A, and (-)-Goniofupyrone by an Asymmetric Acetate Aldol approach

Sandeep AnkiReddy, Praveen AnkiReddy and Gowravaram Sabitha*

Received (in XXX, XXX) Xth XXXXXXXXXX 20XX, Accepted Xth XXXXXXXXXX 20XX
DOI: 10.1039/b000000x

First stereoselective total synthesis of (+)-goniothalesacetate and total synthesis of several bioactive styryl lactones, (+)-altholactone, (+)-gonioheptolide A, and (-)-goniofupyrone have been achieved from an advanced intermediate, which can be derived from L-(+)-DET.

Introduction

Styryl lactones, despite their restricted occurrence in the plant kingdom, are reported to possess cytotoxic, anti-tumour, pesticidal, teratogenic and embryotoxic activities.¹ Therefore they make up an interesting group from a pharmacological point of view. (+)-Goniothalesacetate, (+)-altholactone, (+)-gonioheptolide A, and (-)-goniofupyrone are representatives of the styryl lactones (1-4, Figure 1). Goniothalesacetate (1) was isolated along with other compound from the stems of a southern Taiwan tree *Goniothalamus amuyon*.² The seeds were reported to be useful in the treatment of edema and rheumatism.³ The structure of the compound was determined on the basis of standard spectroscopic methods and the absolute stereochemistry was established from NOESY spectrum and by preparation of *R* & *S* - MTPA esters. Goniothalesacetate has five contiguous stereocenters and its structure was determined as (2*R*,3*R*,4*S*,5*S*,6*R*) methyl 3-(3-acetoxy-4-hydroxy-5-phenyloxolan-2-yl)-3-methoxypropanoate. (+)-Altholactone (2), a styryllactone, tetrahydrofuro[3,2-*b*]pyran-5-one was first isolated in 1977 from a *Polyalthia* species (Annonaceae) by Loder and co-workers⁴ and later, in 1985 from the bark of *Goniothalamus giganteus* by El-Zayat et al.⁵ The flowers of this plant undulate like waves and their scent is sweet and very strong. Altholactone has also been isolated from the Malaysian plant *G. malayanus* and found to induce apoptosis via oxidative stress in human HL-60 leukemia cells^{6a} and displays promising antimicrobial activity.^{6b} (+)-Altholactone (2) is a bicyclic compound presenting an α,β -unsaturated δ -lactone (5-oxygenated-5,6-dihydro-2*H*-pyran-2-one) and a disubstituted furanic motif with a bicyclic *cis* ring junction.

*Natural Products Chemistry Division, ^bChemical Biology Laboratory, CSIR-Indian Institute of Chemical Technology, Hyderabad 500 607, India. E-mail: gowravaramsr@yahoo.com, sabitha@iict.res.in; Fax: +91-40-27160512

[†]Electronic supplementary information (ESI) available: ¹H and ¹³C NMR spectra of all compounds.

This natural product exhibits a very interesting cytotoxicity to mice during the P388 *in vivo* antileukemic screen (toxic at 45 mg/kg and 118% T/C at 25 mg/kg) and is lethal to brine shrimp, *Artemia salina* (LC50 = 234 μ g/mL, 9 KB cytotoxicity ED50 = 2 μ g/mL).⁵ Additionally, it was known to possess broad spectrum immune modulating activity by inhibiting the activation of pro-inflammatory cytokines RAW 264.7 cell lines.⁷ Altholactone induces reactive oxygen species-mediated apoptosis in bladder cancer T24 cells through mitochondrial dysfunction, MAPK-p38 activation and Akt suppression.⁸ Therefore, this lactone has been the target of synthetic efforts by several groups.⁹ In 1993, gonioheptolide A (3) has been isolated from the bark extract of *Goniothalamus giganteus*.¹⁰ Later in 1999, the structure of gonioheptolide A¹¹ was unambiguously revised as (1'*R*,2*S*,3*S*,4*S*,5*R*)-3,4-dihydroxy-2-[(19-hydroxy-29-methoxycarbonyl)ethyl]-5-phenyltetrahydrofuran by its racemic synthesis from (\pm)-goniofupyrone. The absolute configuration of (+)-gonioheptolide A was established in 2007¹² by its total synthesis. It showed marginal cytotoxicity to certain human solid tumor cells in culture.¹³ Goniofupyrone (4) was also isolated from the stem bark of *Goniothalamus giganteus* (Annonaceae) and significantly cytotoxic to human tumor cells.¹⁴ Its absolute stereochemistry was determined by its synthesis.¹⁵





Figure 1. Chemical structures of styryl lactones 1-4

Eventhough, several total syntheses of **2**,⁹ **3**¹² and **4**,^{9,14} have been reported, to the best of our knowledge, no total synthesis of Goniothalesacetate **1** has been reported. As part of our continuing efforts, in the preparation of biologically active styryl lactones,¹⁶ we now disclose a first stereoselective total synthesis of (+)-goniothalesacetate and total syntheses of (+)-altholactone, (+)-gonioheptolide A and (-)-goniofupyrone from L-(+)-DET via an advanced intermediate.

Scheme 1. Retrosynthesis



The retrosynthetic analysis of **1-4** is shown in Scheme 1. We envisaged that four target molecules (+)- goniothalesacetate, altholactone, gonioheptolide A and goniofupyrone (**1-4**) could be prepared from the common intermediate **5**. C2 And C6 chiral centers in the intermediate **5** could be obtained from Grignard and asymmetric acetate aldol reactions respectively.


Results and Discussion

The synthesis of the key intermediate **5** is illustrated in Scheme 2.

The known allylic alcohol¹⁷ **6** prepared in 6 steps from L-(+)-DET was subjected to Sharpless asymmetric epoxidation¹⁸ using (+)-DET and TBHP to yield the required epoxy alcohol **7** with good stereoselectivity in 85% yield. Iodination under standard conditions followed by zinc reduction¹⁹ of the derived iodo-epoxide afforded secondary allylic alcohol **8** in 86% yield for the two steps. The resulting secondary hydroxyl was protected as its Bn ether to obtain **9** in 90% yield. Oxidative cleavage of the olefin in compound **9** under Jin's one-pot conditions²⁰ using OsO₄-NaIO₄ and 2,6-lutidine in dioxane-water (3:1) furnished the corresponding aldehyde. Due to its inherent lack of stability, aldehyde was used in the next step without further purification. Treatment of the above aldehyde with PhMgBr, generated from PhBr and Mg by Grignard reaction in the presence of MgBr₂.OEt₂²¹ afforded 1,2-*syn* diol **10** in 82% yield and with a diastereomeric ratio of 96:4 (determined by chiral HPLC).²² Following a modification of the Mosher method,²³ the newly created stereogenic center in compound **10** bearing the hydroxyl group was assigned. The syntheses of both the (*S*)- and (*R*)-MTPA esters of **10** were achieved using MTPA acid with DCC as the coupling reagent. The chemical shifts of both the (*S*)- and (*R*)-MTPA esters of **10** were assigned by ¹H NMR. From the equation given in Figure 2, the $\Delta\delta$ values were calculated for as many protons as possible. The carbon chain bearing protons showing $\Delta\delta$ negative values should be placed on the left hand side of the model (Figure 2) whilst that where $\Delta\delta$ has positive values should be placed on the right hand side. From this the center was found to have the *S*-configuration which thus


establishes the absolute stereochemistry of **10**. Next, the hydroxyl group was tosylated in **10** and followed by

Figure 2. $\Delta\delta = (\delta_S - \delta_R) \times 10^3$ for (*S*)- and (*R*)-MTPA esters of compound **10**



removal of acetone under acidic conditions using PTSA in CH₂Cl₂:MeOH (1:1) resulted in the desired 2,5-*syn* tetrahydrofuran **11** in 85% yield over two steps. The secondary hydroxy group was protected as the corresponding silyl ether **12** by treatment with *tert*-butyl(dimethyl)silyl triflate and 2,6-lutidine in 92% yield. Next, removal of the PMB group with DDQ under buffer conditions obtained the free alcohol **13**. To extend the two carbon side chain with a chiral center, it was thought worthwhile to adopt a diastereoselective asymmetric acetate aldol reaction.

Scheme 2. synthesis of advanced intermediate **5**




Accordingly, oxidation of the alcohol using IBX furnished the corresponding aldehyde, which was immediately treated with (4*S*)-3-acetyl-4-benzyl-1,3-thiazolidine-2-thione **14**²⁴ in the presence of titanium(IV) chloride and ethyl(diisopropyl)amine, yielding *syn* isomer **15** as the major diastereomer in a 97:3 ratio (by crude ¹H NMR analysis) (Scheme 2). The resulting aldol adduct was immediately converted to methyl ester using imidazole in methanol to get the pure compound **5** after column chromatography. This advanced intermediate **5** can be utilized for the synthesis of four styryl lactones.

Synthesis of (+)-goniothalesacetate (**1**) and (+)-alholactone (**2**)

Synthesis of goniothalesacetate (**1**) was accomplished in 4 steps from an intermediate **5** (Scheme 3). Accordingly, the free secondary hydroxyl group in **5** was methylated using Meerwein salt to give *O*-methylated compound **16**. Our next task was the removal of TBS group. However, three step sequence occurred (TBS deprotection, β-methoxy elimination, cyclization) in a one-pot reaction by using TBAF in THF to furnish a bicyclic compound **17**, which can be later utilized in the synthesis of alholactone (**2**). Alternatively, a silyl group removal in compound **16** was achieved by treatment with PTSA in DCM:MeOH (1:1) to afford the alcohol **18** in 82% yield, which was subsequently acetylated with acetic anhydride and NEt₃ to give acetate compound **19**. Benzyl ether deprotection in **19** could not be achieved under TiCl₄ conditions, which led to complete decomposition of the starting material. Finally, cleavage of the Bn group was occurred smoothly with SnCl₄ (CH₂Cl₂, 40 °C) to furnish synthetic (+)-goniothalesacetate (**1**) in 90% yield, whose spectroscopic properties (¹H, ¹³C NMR, IR, HRMS) as well as specific rotation ([α]_D) were in full accordance with those reported for natural (+)-**1**.²

The above bicyclic compound **17** formed during the synthesis of goniothalesacetate (refer Scheme 3) was converted into the target compound **2**. Accordingly, removal of benzyl group with TiCl₄²⁵ in **17** led to the formation of alholactone (**2**)⁹ in 90% yield. The physical and spectroscopic data of synthetic **2** were identical to the reported values of the natural product.


Scheme 3. Synthesis of goniothalesacetate (**1**) & alholactone (**2**)



Synthesis of (+)-gonioheptolide A (**3**) and Synthesis of (-)-goniofupyrone (**4**)

With enough compound **5** in hand, we extended our work to the synthesis of gonioheptolide **3**, which was accomplished in a single step (Scheme 4). Thus, global deprotection of Bn and TBS groups in **5** was achieved with TiCl₄ to afford (+)-gonioheptolide A (**3**) in 85% yield. Synthesis of goniofupyrone **4** was accomplished in two steps from an intermediate **5** (Scheme 4). Treatment of **5** with PTSA/DCM deprotection of TBS group and cyclization occurred in one-pot to furnish the lactone **20** in 90% yield. Finally, removal of benzyl group with TiCl₄ in **20** led to the formation of (-)-goniofupyrone (**4**)^{9,14} in 85% yield. The physical and spectroscopic data of synthetic **3** and **4** were identical to the reported values of the natural products.

Scheme 4. Synthesis of gonioheptolide A (**3**) & goniofupyrone (**4**)



Conclusion

We have reported a first stereoselective total synthesis of (+)-goniothalesacetate and total syntheses of (+)-alholactone, (+)-gonioheptolide A and (-)-goniofupyrone using Grignard and asymmetric acetate aldol reactions as the key steps.

Experimental Section

General: All reactions were performed under inert atmosphere.

All glassware apparatus used for reactions are perfectly oven/flame dried. Anhydrous solvents were distilled prior to use: THF from Na and benzophenone; CH₂Cl₂ from CaH₂; MeOH from Mg cake. Commercial reagents were used without purification. Column chromatography was carried out by using silica gel (60–120 mesh). Analytical thin layer chromatography (TLC) was run on silica gel 60 F254 pre-coated plates (250 μm thickness). Optical rotations [α]_D²⁵ were measured on a polarimeter and given in 10⁻¹ deg cm² g⁻¹. Infrared spectra were recorded in CHCl₃/KBr (as mentioned) and reported in wave number (cm⁻¹). Mass spectral data were obtained using MS (EI) ESI, HRMS mass spectrometers. High resolution mass spectra (HRMS) [ESI⁺] were obtained using either a TOF or a double focusing spectrometer. ¹H NMR spectra were recorded at 300, 400, 500 and ¹³C NMR spectra 75, 125 MHz in CDCl₃ solution unless otherwise mentioned, chemical shifts are in ppm downfield from tetramethylsilane and coupling constants (*J*) are reported in hertz (Hz). The following abbreviations are used to designate signal multiplicity: s = singlet, d = doublet, t = triplet, q

= quartet, m = multiplet, br = broad. The diastereomeric purity was determined by HPLC.

((2*S*,3*R*)-3-((4*R*,5*S*)-5-((4-methoxybenzyloxy)methyl)-2,2-

dimethyl-1,3-dioxolan-4-yl)oxiran-2-yl)methanol (7): To a

freshly flame dried double necked round bottom flask equipped with activated molecular sieves (4 Å) (5 g) and dry CH₂Cl₂ (30 mL) at -20 °C were added Ti(O^{*i*}Pr)₄ (1.14 mL, 3.89 mmol), D-

(+)-diisopropyl tartrate (0.86 g, 3.89 mmol) and the mixture was stirred for 30 min. To this reaction mixture, allyl alcohol **6** (6.0 g,

19.4 mmol) followed by an interval of 30 min, TBHP (5.9 mL, 29.20 mmol, 5 M solution in CH₂Cl₂) was then added and stirring was continued till completion of the reaction (8 h). The reaction mixture was warmed to 0 °C, filtered through Celite. The filtrate was quenched with water (1 mL), 15% aqueous NaOH solution

(1 mL) and stirred vigorously for 1 h. The biphasic solution was separated and the aqueous layer was extracted with CH₂Cl₂ (3 × 20 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under vacuum. The crude residue was purified by column chromatography (7:3 hexane-

EtOAc) to afford the pure epoxide **7** (5.36 g, 85%) as a colorless oil. [α]_D²⁵ = -7.5 (c 0.18, CHCl₃); **IR** (neat): 3452, 2987, 2868, 1612, 1513, 1248, 1089 cm⁻¹; **¹H NMR** (300 MHz, CDCl₃): δ 7.27-7.23 (m, 2H), 6.88 (d, *J* = 8.5 Hz, 2H), 4.50 (s, 3H), 4.15-4.11 (m, 1H), 3.84 (dd, *J* = 12.9, 2.1 Hz, 1H), 3.81 (s, 3H), 3.77

(dd, *J* = 8.2, 5.0 Hz, 1H), 3.66 (dd, *J* = 9.9, 4.8 Hz, 1H), 3.59-3.52 (m, 2H), 3.10-3.06 (m, 2H), 1.41 (s, 3H), 1.40 (s, 3H). **¹³C NMR** (CDCl₃, 75 MHz): δ 159.3, 129.6, 129.5, 113.7, 110.0, 78.7, 76.4, 73.0, 69.7, 60.5, 55.6, 55.2, 54.5, 26.9, 26.5. HRMS (ESI): *m/z* calcd for C₁₇H₂₄O₆Na [M+Na]⁺: 347.1450, found = 347.1465.

(*R*)-1-((4*S*,5*S*)-5-((4-methoxybenzyloxy)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)prop-2-en-1-ol (8): To a stirred solution of **7** (5.1 g, 15.7 mmol) in Et₂O-MeCN (3:1, 20 mL) were added TPP (6.2 g, 23.6 mmol) and imidazole (2.14 g, 31.5 mmol) at 0 °C and the mixture stirred for 5 min. I₂ (6.0 g, 23.6 mmol) was added at 0

°C and stirred for 1 h. The reaction mixture was quenched with sat. aq Na₂S₂O₃ (20 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with H₂O (10 mL), brine (10 mL), and dried (Na₂SO₄). The solvent was evaporated in vacuo to afford the crude iodo compound. This was used for

the next step without further purification. To a stirred solution of the above iodo compound in EtOH (20 mL) was added activated Zn dust (3.66 g, 56.4 mmol) and the mixture stirred at reflux for 1-2 h. The mixture was passed through a short pad of Celite. The filtrate was concentrated and the residue was purified by column

chromatography on silica gel (eluent: PE-EtOAc, 8:2) to afford **8** (4.16 g, 86%) as a colorless liquid. [α]_D²⁵ = + 10.7 (c 0.24, CHCl₃); **IR** (neat): 3454, 2987, 2867, 1612, 1513, 1248, 1081 cm⁻¹; **¹H NMR** (300 MHz, CDCl₃): δ 7.27- 7.23 (m, 2H), 6.88 (d, *J* = 8.6 Hz, 2H), 5.89-5.81 (m, 1H), 5.35 (dt, *J* = 17.2, 1.5 Hz, 1H),

5.22 (dt, *J* = 10.6, 1.5 Hz, 1H), 4.5 (s, 2H), 4.19-4.08 (m, 2H), 3.86 (dd, *J* = 7.9, 4.4 Hz, 1H), 3.80 (s, 3H), 3.59 (dd, *J* = 10.0, 5.3 Hz, 1H), 3.53 (dd, *J* = 10.0, 4.8 Hz, 1H), 1.43 (s, 3H), 1.42 (s, 3H). **¹³C NMR** (CDCl₃, 75 MHz): δ 159.2, 136.7, 129.6, 129.3, 116.8, 113.7, 109.5, 80.9, 76.0, 73.1, 72.0, 69.8, 55.2, **27.0** (2C). HRMS (ESI): *m/z* calcd for C₁₇H₂₄O₅Na [M+Na]⁺: 331.1504, found = 331.1516

(4*S*,5*S*)-4-((*R*)-1-(benzyloxy)allyl)-5-((4-methoxybenzyloxy)methyl)-2,2-dimethyl-1,3-dioxolane (9): To

a suspension of NaH (60%, 0.7 g, 28.4 mmol) in dry THF (20 mL) was added dropwise a solution of alcohol **8** (3.50 g, 11.3 mmol) in THF (20 mL) at 0 °C. To this reaction mixture TBAI (0.01 g) and benzyl bromide (1.94 mL, 11.3 mmol) were added subsequently and stirring was continued for 2h at same temperature and 6 h at room temperature. The reaction mixture

was quenched by crushed ice flakes until a clear solution (biphasic) formed. The reaction mixture was extracted with ethyl acetate (2 x 30 mL). The organic extracts were washed with water (1 x 50 mL), brine (1 x 50 mL) and dried over anhydrous Na₂SO₄. Evaporation of the solvent followed by column

chromatography (10% EtOAc/hexane) afforded the pure product **9** (4.08 g, 90% yield) as a colorless liquid. [α]_D²⁵ = -22.7 (c 0.22, CHCl₃); **IR** (neat): 2986, 2865, 1611, 1513, 1086 cm⁻¹; **¹H NMR** (300 MHz, CDCl₃): δ 7.38-7.21 (m, 7H), 6.86 (d, *J* = 8.6 Hz, 2H), 5.81-5.67 (m, 1H), 5.36-5.26 (m, 2H), 4.67 (d, *J* = 12.2 Hz, 1H),

4.49 (s, 2H), 4.42 (d, *J* = 12.2 Hz, 1H), 4.16-4.08 (m, 1H), 3.94-3.84 (m, 2H), 3.80 (s, 3H), 3.57 (dd, *J* = 10.5, 3.2 Hz, 1H), 3.46 (dd, *J* = 10.5, 6.2 Hz, 1H), 1.43 (s, 3H), 1.39 (s, 3H). **¹³C NMR** (CDCl₃, 75 MHz): δ 159.0, 134.2, 129.2, 128.2 (2C), 127.5 (2C), 127.4, 119.7, 113.6, 109.6, 80.0, 79.0, 76.7, 72.9, 70.3, 70.2,

55.1, 27.1, 26.9. HRMS (ESI): *m/z* calcd for C₂₄H₃₄O₅N [M+NH₄]⁺: 416.2417, found = 416.2431.

(1*S*,2*R*)-2-(benzyloxy)-2-((4*R*,5*S*)-5-((4-methoxybenzyloxy)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-1-phenylethanol (10): To a solution of **9** (2.4 g, 5.52 mmol) in 1,4-dioxane/water (3:1; 12 mL), 2,6-lutidine (1.7 mL, 16.58 mmol), OsO₄ (2.82 mL, 0.05 mmol) followed by NaIO₄ (5.20 g, 24.8 mmol) were sequentially added at room temperature, and the mixture was stirred for 2 h. After completion of the reaction (monitored by TLC), 1,4-dioxane was removed under reduced

pressure, and the residue was diluted with CH₂Cl₂ (20 mL). The organic layer was separated and the aqueous layer extracted with CH₂Cl₂ (2 x 10 mL). The combined organic layers were quickly washed with 1 N HCl (2 x 5 mL) to remove excess 2,6-lutidine followed by brine (2 x 5 mL), dried with anhydrous Na₂SO₄, and

concentrated under reduced pressure to give the crude aldehyde.

To a suspension of Mg (0.26 g, 11.0 mmol) in anhydrous THF (10 mL) Phenyl bromide (1.72 mL, 11.0 mmol) was added dropwise under nitrogen atmosphere at room temperature. It is allowed to stir for half an hour at room temperature.

In another R.B the crude aldehyde **9a** (2.2 g, 5.5 mmol) dissolved in CH₂Cl₂ (10 mL) under nitrogen condition was added at 0 °C to a stirred suspension of MgBr₂.Et₂O (1.83 g, 7.15 mmol) in CH₂Cl₂. After stirring for 20 min, the flask was cooled to -78 °C and the phenyl Grignard generate above was added slowly at -

78 °C and the reaction was stirred further at this temperature for 1 h. The solvent was then removed in vacuo, after which the residue was diluted with CH₂Cl₂ and allowed to warm to 0 °C. Then, the reaction mixture was quenched with saturated aq NH₄Cl and extracted with CH₂Cl₂ (3 x 30 mL). The combined

organic layers were washed with brine, dried over Na₂SO₄, and the solvent was removed under reduced pressure. The compound was purified by silica gel column chromatography (20% EtOAc/Hexane) to provide **10** (2.1 g, 82%) as yellow oil. [α]_D²⁵ = + 24.3 (c 0.27, CHCl₃); **IR** (neat): 3474, 2987, 2932, 1611, 1513, 1248, 1085 cm⁻¹; **¹H NMR** (300MHz, CDCl₃): δ 7.43- 7.24 (m, 9H), 7.18- 7.14 (m, 3H), 6.85 (d, *J* = 8.6 Hz, 2H), 4.92-4.89 (m,

1H), 4.49 (d, $J = 11.2$ Hz, 1H), 4.44- 4.39 (m, 3H), 4.23 (td, $J = 10.5, 5.2$ Hz, 1H), 3.82-3.79 (m, 4H), 3.60 (dd, $J = 5.0, 3.0$ Hz, 1H), 3.50 (dd, $J = 10.0, 5.2$ Hz, 1H), 3.41 (dd, $J = 9.9, 5.2$ Hz, 1H), 3.09 (d, $J = 3.9$ Hz, 1H), 1.45 (s, 3H), 1.37 (s, 3H). ^{13}C NMR (CDCl₃, 75 MHz): δ 159.1, 141.2, 137.6, 129.8, 129.2, 128.3, 128.2, 128.1, 127.8, 127.5, 126.4, 113.7, 109.1, 81.6, 79.6, 75.5, 74.9, 74.2, 73.0, 69.9, 55.2, 26.9, 26.8. HRMS (ESI) m/z calcd for C₂₉H₃₄O₆Na [M+Na]⁺: 501.2220, found = 501.2247.

(R)-MTPA ester of compound 10: ^1H NMR (500MHz, CDCl₃): δ 7.45- 7.41 (m, 1H), 7.40- 7.35 (m, 4H), 7.33- 7.15(m, 9H), 7.06(d, $J = 8.5$ Hz, 2H), 6.83(d, $J = 8.6$ Hz, 2H), 6.23(d, $J = 9.1$ Hz, 1H), 4.48 (d, $J = 11.6$ Hz, 1H), 4.35 (d, $J = 11.6$ Hz, 1H), 4.31(d, $J = 7.9$ Hz, 2H), 4.05(td, $J = 10.6, 5.3$ Hz, 1H), 3.81- 3.77(m, 4H), 3.40(s, 3H), 3.30-3.26(m, 2H), 3.13(dd, $J = 9.6, 5.8$

Hz, 1H), 1.39(s, 3H), 1.20(s, 3H).
(S)-MTPA ester of compound 10: ^1H NMR (500MHz, CDCl₃): δ 7.37- 7.34 (m, 1H), 7.34- 7.26 (m, 11H), 7.17- 7.13(m, 2H), 7.03(d, $J = 8.6$ Hz, 2H), 6.80(d, $J = 8.6$ Hz, 2H), 6.15(d, $J = 9.3$ Hz, 1H), 4.81 (d, $J = 11.7$ Hz, 1H), 4.57(d, $J = 11.6$ Hz, 1H), 4.30(ABq, $J = 25.4, 11.9$ Hz, 2H), 4.12(m, 1H), 3.82- 3.78(m, 4H), 3.37(s, 3H), 3.33-3.27(m, 2H), 3.14(dd, $J = 9.7, 6.1$ Hz, 1H), 1.45(s, 3H), 1.24(s, 3H).

(2S,3R,4S,5R)-4-(benzyloxy)-2-((4-methoxybenzyloxy)methyl)-5-phenyltetrahydrofuran-3-ol

(11): To a stirred mixture of compound **10** (1.8 g, 3.76 mmol), triethylamine (1.04 mL, 7.53 mmol) and DMAP (cat, 10 mol %) in CH₂Cl₂ (20 mL) at 0 °C was added tosyl chloride (0.86 g, 4.51 mmol) in CH₂Cl₂ (2 mL) was added over 15 min. The reaction was allowed to warm to room temperature and stirred for 2 h. The reaction mixture was quenched with saturated NaHCO₃. The organic layer was extracted with CH₂Cl₂ (2 x 20 mL). The combined organic layers were washed with H₂O (2 x 20 mL), brine solution (2 x 20 mL) and dried over Na₂SO₄. Removal of solvent under reduced pressure to give crude product. Which was used for the next reaction without further purification.

To a stirred solution of compound **10a** (2.1 g, 3.30 mmol) in MeOH: DCM (1:1) 5ml was added PTSA (10 mol%) and the reaction mixture was stirred at r.t. for 3h. The MeOH and DCM was removed under reduced pressure and the crude product was purified by column chromatography on silica gel (eluent: PE–EtOAc, 7:3) to afford the acid **11** (1.16g, 72%) as a viscous liquid; yield: $[\alpha]_{\text{D}}^{25} = + 3.4$ (c 0.52, CHCl₃); **IR** (neat): 3443, 2908, 1611, 1511, 1247, 1032 cm⁻¹; ^1H NMR (300 MHz, CDCl₃): δ 7.45-7.42 (m, 2H), 7.34-7.24 (m, 10H), 6.89 (d, $J = 8.6$ Hz, 2H), 4.79 (d, $J = 4.7$ Hz, 1H), 4.64-4.52 (m, 4H), 4.42 (dd, $J = 4.5, 2.3$ Hz, 1H), 3.96 (dd, $J = 10.5, 4.4$ Hz, 1H), 3.94-3.89 (m, 3H), 3.81 (s, 3H). ^{13}C NMR (CDCl₃, 75 MHz): δ 159.3, 140.2, 137.7, 129.4, 128.3, 127.7, 127.6, 127.5, 126.3, 113.8, 92.0, 84.7, 79.2, 77.9, 73.6, 72.0, 68.6, 55.2. HRMS (ESI) m/z calcd for C₂₆H₂₈O₅Na [M+Na]⁺: 443.1812, found = 443.1829.

((2S,3R,4R,5R)-4-(benzyloxy)-2-((4-methoxybenzyloxy)methyl)-5-phenyltetrahydrofuran-3-yl)oxy(tert-butyl)dimethylsilane (12): A soln of compound **11** (0.72 g, 1.64 mmol) in CH₂Cl₂ (10 mL) was treated with 2,6-lutidine (0.57 mL, 4.93 mmol) at 0 °C and stirred for 20 min. Next, TBSOTf (0.45 mL, 1.97 mmol) was added, and following completion of the reaction as indicated by TLC, the mixture was quenched with sat. NH₄Cl soln and extracted with CH₂Cl₂ (3 x 50

mL). The combined organic layer was dried over anhyd Na₂SO₄, and evaporated under reduced pressure to yield a viscous liquid, which on purification by silica gel column chromatography (EtOAc–hexane, 1:9) afforded the silyl-protected ether **12** (0.81 g, 92%) as a colorless liquid. : $[\alpha]_{\text{D}}^{25} = + 31.2$ (c 0.28, CHCl₃); **IR** (neat): 2929, 2858, 1611, 1513, 1250, 1093 cm⁻¹; ^1H NMR (300 MHz, CDCl₃): δ 7.54-7.30 (m, 12H), 6.98 (d, $J = 8.5$ Hz, 2H), 5.0 (d, $J = 2.3$ Hz, 1H), 4.72- 4.58 (m, 4H), 4.46-4.36 (m, 2H), 3.95-3.84 (m, 6H), 0.90 (s, 9H), 0.21 (s, 3H), 0.12 (s, 3H). ^{13}C NMR (CDCl₃, 75 MHz): δ 159.1, 140.9, 137.6, 130.3, 129.5, 128.4, 128.0, 127.7, 127.5, 127.2, 126.6, 113.7, 92.0, 86.2, 81.3, 77.0, 73.1, 71.8, 68.1, 55.2, 25.5, 17.9, -4.8, -5.3. HRMS (ESI): m/z calcd for C₃₂H₄₆O₅NSi [M+NH₄]⁺: 552.3139, found = 552.3113.

((2S,3R,4R,5R)-4-(benzyloxy)-3-(tert-butyl)dimethylsilyloxy)-5-phenyltetrahydrofuran-2-yl)methanol (13): To an ice-bath cooled solution of compound **12** (0.7 g, 1.31 mmol) in 10 mL aq CH₂Cl₂ (CH₂Cl₂:H₂O, 9:1), DDQ (0.32 g, 1.44 mmol) was added and the reaction mixture was stirred for 1 h at 0 °C. The reaction mixture was washed with 5% aq NaHCO₃ solution (10 mL). The layers were separated and the aqueous layer was extracted twice with CH₂Cl₂ (2 x 10). The combined organic extracts were washed with water, dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The crude product was purified by column chromatography (15% EtOAc/hexane) to afford alcohol **13** (0.46 g, 85 % yield) as a liquid. $[\alpha]_{\text{D}}^{25} = + 29.0$ (c 0.20, CHCl₃); **IR** (neat): 3451, 2931, 2858, 1606, 1460, 1072 cm⁻¹; ^1H NMR (300 MHz, CDCl₃): δ 7.46-7.44 (m, 2H), 7.35-7.24 (m, 8H), 4.88 (d, $J = 3.9$ Hz, 1H), 4.51 (ABq, $J = 20.2, 11.5$ Hz, 2H), 4.38 (dd, $J = 4.4, 2.3$ Hz, 1H), 4.25-4.21 (m, 1H), 4.01 (dd, $J = 11.9, 5.7$ Hz, 1H), 3.92-3.87 (m, 2H), 0.83 (s, 9H), 0.07 (s, 3H), -0.04 (s, 3H). ^{13}C NMR (CDCl₃, 75 MHz): δ 140.5, 137.4, 128.4, 128.3, 127.8, 127.6, 126.6, 91.8, 85.1, 81.5, 77.9, 72.1, 62.3, 25.5, 17.8, -4.8, -5.2. HRMS (ESI) m/z calcd for C₂₄H₃₄O₄NaSi [M+Na]⁺: 437.2096, found = 437.2118.

(R)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-3-((2S,3S,4R,5R)-4-(benzyloxy)-3-(tert-butyl)dimethylsilyloxy)-5-phenyltetrahydrofuran-2-yl)-3-hydroxypropan-1-one (15): To a stirred solution of **13** (0.24g, 1.04 mmol) in dryCH₂Cl₂ (5 mL) at 0 °C under argon, freshly distilled TiCl₄ (0.11 mL, 1.06 mmol) was added slowly. After 15 min, DIPEA (0.2 mL, 1.16 mmol) was added dropwise and stirred for 1 h at 0 °C. The reaction mixture was cooled to -78 °C and stirred another 1 h before the addition of aldehyde **14** (0.43 g dissolved in 5 mL of dry CH₂Cl₂, 1.04 mmol). The reaction was continued 15 min further at -78 °C prior to quench with saturated aqueous NH₄Cl (10 mL). The mixture was extracted with EtOAc (2 x 50 mL), washed with water and brine, dried over Na₂SO₄, and concentrated *in vacuo*. Purification by column chromatography (SiO₂, 100–200 mesh, 20–30% EtOAc in hexane) of crude residue resulted aldol adduct **15** (0.41 g, 60% over 2 steps) as a white solid. Attempts toward crystallization from (20% EtOAc/hexane) gave a yellow oil. $[\alpha]_{\text{D}}^{25} = + 10.9$ (c 0.45, CHCl₃); **IR** (neat): 3455, 2928, 2856, 1695, 1456, 1255, 1042 cm⁻¹; ^1H NMR (300 MHz, CDCl₃): δ 7.47-7.44 (m, 2H), 7.37-7.25 (m, 13H), 4.96 (d, $J = 3.3$ Hz, 1H), 4.73-4.68 (m, 1H), 4.60 (d, $J = 11.9$ Hz, 1H), 4.52 (d, $J = 11.7$ Hz, 1H), 4.37 (dd, $J = 4.1, 1.9$ Hz, 1H), 3.91 (dd, $J = 3.5, 2.1$ Hz, 1H), 3.63- 3.53 (m, 2H), 3.27-3.19 (m, 2H), 3.08-2.98 (m, 2H),

2.89 (dd, $J = 16.4, 11.5$ Hz, 2H), 0.78 (s, 9H), 0.07 (s, 3H), -0.15 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 201.1, 171.5, 140.5, 137.3, 136.4, 129.4, 129.2, 128.9, 128.8, 128.4, 128.2, 127.9, 127.7, 127.5, 127.2, 127, 126.5, 113.9, 91.3, 85.1, 83.2, 78, 72, 68.5, 67.2, 42.5, 36.5, 31.9, 25.5, 17.7, -4.5, -5.1. HRMS (ESI): m/z calcd for $\text{C}_{36}\text{H}_{46}\text{O}_5\text{NS}_2\text{Si}$ $[\text{M}+\text{H}]^+$: 664.2564, found = 664.2581.

(R)-methyl 3-((2S,3S,4R,5R)-4-(benzyloxy)-3-(tert-butylidimethylsilyloxy)-5-phenyltetrahydrofuran-2-yl)-3-hydroxypropanoate (5):

Imidazole (0.41 g, 6.0 mmol) was added to a stirred solution of the compound **15** (0.40 g, 0.60 mmol) in MeOH (10 mL). After stirring overnight the yellow solution became colorless and then EtOAc (10 mL) and saturated NaHCO_3 (10 mL) solutions were added. The layers were separated and the aqueous layer was extracted with EtOAc (3×5 mL). The combined organic layers were dried with MgSO_4 , filtered, and concentrated in vacuo. Flash chromatography (petroleum ether/EtOAc, 8:2) provided methyl ester **5** (0.26 g, 90%) as a colorless oil. $[\alpha]_{\text{D}}^{25} = +4.1$ (c 0.32, CHCl_3); IR (neat): 3449, 2929, 2857, 1741, 1457, 1255, 1078 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.48-7.44 (m, 2H), 7.35-7.24 (m, 8H), 4.89 (d, $J = 3.9$ Hz, 1H), 4.54 (d, $J = 11.5$ Hz, 1H), 4.51-4.46 (m, 2H), 4.39 (dd, $J = 4.4, 2.7$ Hz, 1H), 4.10-4.08 (m, 1H), 3.91 (dd, $J = 3.9, 2.4$ Hz, 1H), 3.72 (s, 3H), 2.74-2.61 (m, 2H), 0.81 (s, 9H), 0.08 (s, 3H), -0.09 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 172.0, 140.4, 137.3, 129.2, 128.8, 128.4, 128.3, 128.1, 127.9, 127.7, 127.6, 126.5, 126.4, 91.3, 84.6, 82.1, 78.3, 72.1, 67.7, 51.7, 37.9, 25.5, 17.7, -4.6, -4.2. HRMS (ESI) m/z calcd for $\text{C}_{27}\text{H}_{39}\text{O}_6\text{Si}$ $[\text{M}+\text{H}]^+$: 487.2490, found = 487.2510.

(R)-methyl 3-((2S,3S,4R,5R)-4-(benzyloxy)-3-(tert-butylidimethylsilyloxy)-5-phenyltetrahydrofuran-2-yl)-3-methoxypropanoate (16):

To a solution of alcohol **5** (0.1 g, 0.20 mmol) in DCM (5 mL) at 0°C was added Proton Sponge (0.13 g, 0.60 mmol) followed by trimethyloxonium tetrafluoroborate (0.09 g, 0.60 mmol). The reaction mixture was stirred for 6 h, before being quenched with NaHCO_3 (5 mL), filtered through Celite, and extracted with DCM (2×5 mL). The combined organic extracts were washed with 1 N. HCl (6 mL), dried (MgSO_4) and concentrated in vacuo. Purification by flash chromatography (hexanes/ EtOAc, 9:1) afforded methyl ether **16** (0.08 g, 78%) as a colourless oil. $[\alpha]_{\text{D}}^{25} = +8.2$ (c 0.25, CHCl_3); IR (neat): 2953, 1740, 1650, 1076 cm^{-1} ; ^1H NMR (300MHz, CDCl_3): δ 7.45-7.42 (m, 2H), 7.35- 7.21 (m, 8H), 4.95 (d, $J = 3.2$ Hz, 1H), 4.60 (d, $J = 11.7$ Hz, 1H), 4.52 (d, $J = 11.7$ Hz, 1H), 4.22 (dd, $J = 3.5, 1.9$ Hz, 1H), 4.14- 4.07 (m, 2H), 3.87 (dd, $J = 3.0, 1.9$ Hz, 1H), 3.71 (s, 3H), 3.57 (s, 3H), 2.60- 2.55 (m, 2H), 0.80 (s, 9H), 0.02 (s, 3H), -0.19 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 171.6, 141, 137.5, 128.4, 128.1, 127.9, 127.7, 127.3, 126.4, 90.7, 85.7, 84.3, 77.1, 76.8, 71.8, 59.3, 51.6, 36.7, 25.6, 17.8, -4.3, -5.2. HRMS (ESI) m/z calcd for $\text{C}_{28}\text{H}_{40}\text{O}_6\text{SiNa}$ $[\text{M}+\text{Na}]^+$: 523.2481, found = 523.2481.

(R)-methyl 3-((2R,3S,4S,5R)-4-(benzyloxy)-3-hydroxy-5-phenyltetrahydrofuran-2-yl)-3-methoxypropanoate (18):

To a stirred solution of compound **16** (0.052 g, 0.10 mmol) in MeOH:DCM (1:2, 5 mL) was added PTSA (10 mol%) and the reaction mixture was stirred at r.t. for 4 h. The MeOH was removed under reduced pressure and the crude product was purified by column chromatography on silica gel (eluent: PE-

EtOAc, 8:2) to afford the acid **18** (0.032, 82%) as a viscous liquid; yield. $[\alpha]_{\text{D}}^{25} = +25.0$ (c 0.15, CHCl_3); IR (neat): 3449, 2924, 2854, 1738, 1636, 1215, 1098 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.44-7.42 (m, 2H), 7.35-7.26 (m, 8H), 4.81 (d, $J = 4.2$ Hz, 1H), 4.60 (ABq, $J = 18.7, 11.7$ Hz, 2H), 4.35-4.32 (m, 1H), 4.21-4.17(m, 1H), 4.13 (dd, $J = 4.7, 3.9$ Hz, 1H), 3.91 (dd, $J = 4.1, 1.6$ Hz, 1H), 3.71 (s, 3H), 3.51 (s, 3H), 2.82 (dd, $J = 18.3, 6.2$ Hz, 2H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 172.0, 140.2, 137.6, 128.4, 128.3, 127.8, 127.6, 126.2, 92.1, 84.9, 81.8, 77.1, 72.1, 58.0, 51.9, 35.9 HRMS (ESI): m/z calcd for $\text{C}_{22}\text{H}_{26}\text{O}_6$ Na $[\text{M}+\text{Na}]^+$: 409.1606, found = 409.1621.

(R)-methyl 3-((2S,3S,4R,5R)-3-acetoxy-4-(benzyloxy)-5-phenyltetrahydrofuran-2-yl)-3-methoxypropanoate(19):

Anhydrous Et_3N (0.018 mL, 0.13 mmol), Ac_2O (0.006 mL, 0.06 mmol), and DMAP (10 mg) were added to a solution of alcohol **18** (20 mg, 0.05 mmol) in anhydrous CH_2Cl_2 (5 mL) under nitrogen atmosphere at room temperature. The mixture was stirred at room temperature for 30 min. The reaction mixture was quenched with saturated NaHCO_3 . The organic layer was extracted with CH_2Cl_2 (2×5 mL). The combined organic layers were dried over Na_2SO_4 . The solvent was removed under reduced pressure, and the mixture was purified by silica gel column chromatography (10% EtOAc/hexane) to afford **19** (21 mg, 95%) as a colorless liquid. $[\alpha]_{\text{D}}^{25} = +30.4$ (c 0.12, CHCl_3); IR (neat): 2927, 1741, 1646, 1231, 1097 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.38-7.26 (m, 10H), 5.24 (dd, $J = 3.5, 1.1$ Hz, 1H), 4.89 (d, $J = 3.9$ Hz, 1H), 4.77 (d, $J = 11.9$ Hz, 1H), 4.59 (d, $J = 12.1$ Hz, 1H), 4.27 (dd, $J = 7.8, 3.5$ Hz, 1H), 4.14-4.08 (m, 1H), 3.84 (dd, $J = 4.0, 1.1$ Hz, 1H), 3.71 (s, 3H), 3.56 (s, 3H), 2.55-2.51 (m, 2H), 2.02 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 171.4, 170.1, 140.0, 139.2, 128.4, 128.3, 127.8, 127.7, 127.6, 125.8, 89.9, 85.8, 82.4, 77.2, 76.5, 72.1, 59.3, 51.8, 36.8. HRMS (ESI): m/z calcd for $\text{C}_{24}\text{H}_{28}\text{O}_7$ Na $[\text{M}+\text{Na}]^+$: 451.1711, found = 451.1727.

(R)-methyl 3-((2S,3S,4R,5R)-3-acetoxy-4-hydroxy-5-phenyltetrahydrofuran-2-yl)-3-methoxypropanoate (1):

To a stirred solution of compound **19** (9 mg, 0.02 mmol) in anhydrous CH_2Cl_2 (5 mL) was added SnCl_4 (1 M solution in DCM, 0.04 mL, 0.04 mmol) at 40°C and the reaction mixture was stirred at the same temperature for 1 h. The reaction mixture was quenched with solid NaHCO_3 (5 mg) and filtered, the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (70% EtOAc/hexane) to afford **1** (7 mg, 90%) as a colorless yellow oil. $[\alpha]_{\text{D}}^{25} = +3.02$ (c 0.32, CH_3OH); lit^2 $[\alpha]_{\text{D}}^{25} = +1.03$ (c 0.39, CH_3OH); IR (neat): 3451, 2923, 2853, 1740, 1632, 1237, 1046 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.45 (d, $J = 7.1$ Hz, 2H), 7.38-7.28 (m, 3H), 5.0 (dd, $J = 5.1, 2.6$ Hz, 1H), 4.71 (d, $J = 6.1$ Hz, 1H), 4.31 (dd, $J = 6.9, 5.2$ Hz, 1H), 4.08 (dd, $J = 3.7, 2.8$ Hz, 1H), 4.05 (td, $J = 6.9, 1.1$ Hz, 1H), 3.72 (s, 3H), 3.55 (s, 3H), 2.60-2.58 (m, 2H), 2.08 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 171.5, 171.4, 139.4, 128.3, 127.8, 125.9, 84.9, 83.5, 81.9, 80.9, 77.2, 59.2, 51.8, 36.5. ^1H NMR (300MHz, CD_3OD): δ 7.44 (d, $J = 7.3$ Hz, 2H), 7.34 (t, $J = 7.3$ Hz, 2H), 7.27(tt, $J = 6.5, 1.2$ Hz, 1H), 5.08 (dd, $J = 4.2, 2.4$ Hz, 1H), 4.70 (d, $J = 6.1$ Hz, 1H), 4.26 (dd, $J = 7.1, 4.2$ Hz, 1H), 4.03 (dd, $J = 4.4, 2.4$ Hz, 1H), 3.99 (td, $J = 7.3, 4.4$ Hz, 1H), 3.69 (s, 3H), 3.51 (s, 3H), 2.58 (d, $J = 4.6$ Hz, 1H), 2.56 (d, $J = 7.6$ Hz, 1H), 1.98 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 173.2, 171.8, 141.7,

129.3, 127.1, 88.1, 83.3, 82.9, 81.2, 78.2, 59.3, 52.3, 37.5, 20.7. HRMS (ESI): m/z calcd for $C_{17}H_{22}O_7Na$ $[M+Na]^+$: 361.1257, found = 361.1247.

(2R,3R,3aR,7aS)-3-(benzyloxy)-2-phenyl-3,3a-dihydro-2H-furo[3,2-b]pyran-5(7aH)-one (17): To a solution of **16** (30 mg, 0.06 mmol) in anhydrous THF (5 mL) was added TBAF (0.12 mL, 0.12 mmol, 1 M soln. in THF) dropwise at 0 °C, and the mixture was stirred for 2 h. H₂O (5 mL) was added, and the mixture was extracted with ethyl acetate (2 x 5 mL). The org. extracts were washed with brine (5 mL) and dried over anhydrous Na₂SO₄. After evaporation of the solvent, the residue was purified by column chromatography (30% EtOAc/hexane) to furnish the bi cyclic compound **17** (15 mg, 82% yield) as colorless solid. M.P. 89-91°C; $[\alpha]_D^{25} = +11.27$ (*c* 0.29, CHCl₃); IR (neat): 2920, 1734, 1639, 1245, 1096 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.35-7.26 (m, 10H), 7.0 (dd, *J* = 9.9, 5.2 Hz, 1H), 6.25 (d, *J* = 9.9 Hz, 1H), 5.01 (dd, *J* = 4.7, 1.3 Hz, 1H), 4.85 (d, *J* = 5.4 Hz, 1H), 4.68 (d, *J* = 11.5 Hz, 1H), 4.62-4.57 (m, 2H), 4.24 (dd, *J* = 5.3, 1.3 Hz, 1H). ¹³C NMR (CDCl₃, 75 MHz): δ 160.1, 139.4, 138.2, 136.8, 128.6, 128.5, 128.3, 128.1, 127.7, 126.2, 124.2, 90.7, 85.3, 84.2, 72.6, 68.7. HRMS (ESI): m/z calcd for $C_{20}H_{19}O_4$ $[M+H]^+$: 323.1270, found = 323.1277.

(2R,3R,3aS,7aS)-3-hydroxy-2-phenyl-3,3a-dihydro-2H-furo[3,2-b]pyran-5(7aH)-one (2): To a stirred solution of compound **17** (10 mg, 0.03 mmol) in anhydrous CH₂Cl₂ (5 mL) was added TiCl₄ (1 M solution in DCM, 0.06 mL, 0.06 mmol) at 0 °C and the reaction mixture was stirred at the same temperature for 1 h. The reaction mixture was quenched with solid NaHCO₃ (20 mg) and filtered, the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (40% EtOAc/hexane) to afford **2** (6.4 mg, 90%) as a colorless solid. M.p. 108-110°C; $[\alpha]_D^{25} = +115.6$ (*c* 0.52, CHCl₃); lit⁴ $[\alpha]_D^{25} = +118.6$ (*c* 0.5, CHCl₃); IR (neat): 3433, 2923, 1729, 1638, 1251, 1093 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.36-7.28 (m, 5H), 6.99 (dd, *J* = 9.9, 5.0 Hz, 1H), 6.22 (d, *J* = 9.9 Hz, 1H), 4.92 (dd, *J* = 5.0, 2.2 Hz, 1H), 4.73 (d, *J* = 5.6 Hz, 1H), 4.63 (t, *J* = 5.0 Hz, 1H), 4.44 (dd, *J* = 6.1, 2.2 Hz, 1H), 3.36 (Brs, 1H). ¹³C NMR (CDCl₃, 75 MHz): δ 161.4, 140.4, 138.1, 128.6, 128.3, 126.1, 123.5, 86.4, 85.9, 83.5, 68.1. HRMS (ESI): m/z calcd for $C_{13}H_{13}O_4$ $[M+H]^+$: 233.0804, found = 233.0808.

(2R,3R,3aS,7R,7aS)-3-(benzyloxy)-7-hydroxy-2-phenyltetrahydro-2H-furo[3,2-b]pyran-5(6H)-one (20): A stirred solution of **5** (25 mg, 0.05 mmol) in DCM (5 mL) was treated with *p*-TSA (10%, 0.25 mmol) for 3 h at 40°. After completion of the reaction (indicated by TLC), reaction mixture was diluted with DCM (5 mL) and solid NaHCO₃ (0.34 g, 4.0 mmol) was added and stirred for further 15 min. The reaction mixture was then filtered through a short pad of Celite and the Celite pad was washed with DCM (3 x 10 mL). Evaporation of solvent followed by silica gel column chromatography of the resulting residue using EtOAc as eluent yielded **20** (14 mg, 81%) as a colourless oil. $[\alpha]_D^{25} = +38.35$ (*c* 0.19, CHCl₃); IR (neat): 3432, 2922, 1741, 1496, 1055 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.38-7.25 (m, 10H), 5.07 (dd, *J* = 4.8, 1.8 Hz, 1H), 4.82 (d, *J* = 6.1 Hz, 1H), 4.68 (d, *J* = 11.5 Hz, 1H), 4.55 (d, *J* = 11.5 Hz, 1H), 4.44 (dt, *J* = 7.6, 3.8 Hz, 1H), 4.33-4.31 (m, 1H), 4.09 (dd, *J* = 6.1, 1.9 Hz, 1H), 2.91 (dd, *J* = 16.7, 3.6 Hz, 1H),

2.67 (dd, *J* = 16.1, 5.3 Hz, 1H). ¹³C NMR (CDCl₃, 75 MHz): δ 168.4, 138.1, 136.8, 128.6, 128.5, 128.3, 128.0, 127.7, 126, 90.4, 84.9, 84.2, 77.0, 72.6, 65.8, 35.2. HRMS (ESI): m/z calcd for $C_{20}H_{24}O_5N$ $[M+NH_4]^+$: 358.1641, found = 358.1649.

(R)-methyl 3-((2S,3S,4S,5R)-3,4-dihydroxy-5-phenyltetrahydrofuran-2-yl)-3-hydroxypropanoate (3): To a stirred solution of compound **5** (11 mg, 0.02 mmol) in anhydrous CH₂Cl₂ (5 mL) was added TiCl₄ (1 M solution in DCM, 0.04 mL, 0.044 mmol) at 0 °C and the reaction mixture was stirred at the same temperature for 1 h. The reaction mixture was quenched with solid NaHCO₃ (20 mg) and filtered, the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (80% EtOAc/hexane) to afford **3** (5.4 mg, 85%) as a colorless oil; $[\alpha]_D^{25} = -2.80$ (*c* 0.29, CHCl₃); lit¹² $[\alpha]_D^{25} = -5.0$ (*c* 0.3, CHCl₃); IR (neat): 3405, 2924, 1727, 1440, 1044 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.48-7.44 (m, 1H), 7.37-7.27 (m, 4H), 4.58 (d, *J* = 6.5 Hz, 1H), 4.45-4.38 (m, 1H), 4.35-4.30 (m, 1H), 4.10-4.06 (m, 2H), 3.71 (s, 3H), 2.86 (dd, *J* = 16.4, 8.6 Hz, 1H), 2.65 (dd, *J* = 16.6, 4.1 Hz, 1H). ¹³C NMR (CDCl₃, 75 MHz): δ 173.2, 139.4, 128.5, 128, 126.4, 84.4, 83.8, 79.8, 67.8, 52.0, 37.6. HRMS (ESI): m/z calcd for $C_{14}H_{18}O_6Na$ $[M+Na]^+$: 305.0985, found = 305.0995.

(2R,3R,3aS,7R,7aS)-3,7-dihydroxy-2-phenyltetrahydro-2H-furo[3,2-b]pyran-5(6H)-one (4): To a stirred solution of compound **20** (9 mg, 0.02 mmol) in anhydrous CH₂Cl₂ (5 mL) was added TiCl₄ (1 M solution in DCM, 0.05 mL, 0.05 mmol) at 0 °C and the reaction mixture was stirred at the same temperature for 1 h. The reaction mixture was quenched with solid NaHCO₃ (20 mg) and filtered, the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (50% EtOAc/hexane) to afford **4** (5.84 mg, 87%) as a colorless oil. $[\alpha]_D^{25} = -6.52$ (*c* 0.34, CHCl₃); lit¹² $[\alpha]_D^{25} = -5.0$ (*c* 0.3, CHCl₃); IR (neat): 3393, 2923, 1734, 1452, 1049 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.32-7.24 (m, 5H), 4.94 (dd, *J* = 5.0, 2.3 Hz, 1H), 4.62 (d, *J* = 6.2 Hz, 1H), 4.33-4.24 (m, 2H), 4.17 (dd, *J* = 6.2, 2.3 Hz, 1H), 3.91 (Brs, 1H), 2.79 (dd, *J* = 17, 3.5 Hz, 1H), 2.62 (dd, *J* = 16.7, 4.5 Hz, 1H). ¹³C NMR (CDCl₃, 75 MHz): δ 170.6, 137.9, 128.6, 128.3, 125.9, 87, 85.4, 83.3, 75.8, 65.3, 34.8. HRMS (ESI): m/z calcd for $C_{13}H_{15}O_5$ $[M+H]^+$: 251.0908, found = 233.0900.

Acknowledgements

SA and PA thank CSIR, New Delhi for the award of fellowships. All the authors thank CSIR, New Delhi, India for financial support as part of XII Five Year plan programme under title ORIGIN (CSC-0108).

Notes and references

- a) X. P. Fang.; J. E. Anderson.; C. J. Chang.; J. L. McLaughlin.; P. E. Fanwick. *J. Nat. Prod.* **1991**, *54*, 1034-1043; b) X. P. Fang.; J. E. Anderson.; C. J. Chang.; J. L. McLaughlin.; P. E. Fanwick. *Tetrahedron* **1991**, *47*, 9751-9758; c) T. W. Sam.; C. Sew-Yeu.; S. Matsjeh.; E. K. Gan.; D. Razak.; A. L. Mohamed. *Tetrahedron Lett.* **1987**, *28*, 2541-2544.
- Y-H. LAN.; F-R. CHANG.; Y-L. YANG and Y-C. WU. *Chem. Pharm. Bull.* **2006**, *54*(7) 1040-1043.

3. W. S. Kan. "Pharmaceutical Botany," National Research Institute of Chinese Medicine, Taipei, **1979**, p. 247.
4. J. W. Loder.; R. H. Nearn.; Altholactone, a Novel from a Polyalthia Species (Annonaceae), *Heterocycles* **1977**, *7*, 113-118.
5. A. E. El-Zayat.; N. R. Ferrigni.; T. G. McCloud.; A. T. McKenzie.; S. R. Byrn.; J. M. Cassidy.; C. J. Chang.; J. L. McLaughlin. *Tetrahedron Lett.* **1985**, *26*, 955-956.
6. a) SH. Inayat-Hussain.; AB Osman.; LB Din.; N. Taniguchi. *Toxicol Lett.* **2002**, *131*(3):153-9. b) F. Al Momani.; A. S. Alkofahi and N. M. Mhaidat. *Molecules* **2011**, *16*, 4560-4566.
7. T. A. Johnson.; J. Sohn.; A. E. Ward.; T. L. Cohen.; N. D. Lorig-Roach.; H. Chen.; R. A. Pilli.; E. A. Widjaja.; M. Hanafi.; L. B. S. Kardono.; P. D. Lotulung.; K. Boundy-Mills.; L. F. Bjeldanes. *Bioorg. Med. Chem.* **2013**, *21*, 4358-4364.
8. B Zhao and Xiaomeng, Li *oncology reports* **2014**, 2769-2775. DOI:10.3892/or.2014.3126.
9. a) A. Favre.; F. Carreaux.; M. Deligny and B. Carboni. *Eur. J. Org. Chem.* **2008**, 4900-4907. b) D. Enders.; J. Barbion. *Chem. Eur. J.* **2008**, *14*, 2842-2849. c) S. Ho Kang. W. Joo kim. *Tetrahedron Lett.* **1989**, *30*, 5915-5918. d) J. Gesson.; J. Jacquesy.; M. Mondon. *Tetrahedron Lett.* **1987**, *28*, 3949-3942.
10. X. P. Fang.; J. E. Anderson.; X. X. Qiu.; J. F. Koxlowski.; C. J. Chang and J. L. McLaughlin. *Tetrahedron* **1993**, *49*, 1563-1570.
11. C. Mukai.; H. Yamashita.; S. Hirai.; M. Hanaoka.; J. L. McLaughlin. *Chem. Pharm. Bull.* **1999**, *47*, 131.
12. S. Gupta.; M. Rajagopalan.; M. M. Alhamadsheh.; L. M. Viranga Tillekeratne.; R. A. Hudson. *Synthesis* **2007**, *22*, 3512-3518.
13. a) D. J. Giad.; S. A. Aronson.; G. J. Todaro.; P. Amstein.; J. H. Kersey.; Do& R; W. P. Parks. *J. Natl. Cancer Inst.* **1973**, *51*, 1417-1423. b) H. D. Soul.; J. Vaques.; A. Long.; S. Albert.; M. Brennan. *J. Natl. Cancer Inst.* **1973**, *51*, 1409-1416. c) J. Fogh.; G. Tmnp. In *Human Tumor Cells in vitro*. Ed by J. Fogh., Plenum Press, New York, **1975**, pp. 115-159.
14. X. P. Fang.; J. E. Anderson.; C. J. Chang.; J. L. McLaughlin.; P. E. Fanwick. *Tetrahedron* **1991**, *47*, 9751-9758.
15. a) C. Mukai.; S. Hirai and M. Hanaoka. *J. Org. Chem.* **1997**, *62*, 6619. b) C. Mukai.; S. Hirai and M. Hanaoka. *Tetrahedron Lett.* **1987**, *28*, 3949-3942.
16. a) A. Raju and G. Sabitha. *RSC Adv* **2015**, *5*, 34040-34046. b) A. M. Reddy.; G. Sabitha.; K. Sirisha. *RSC Adv* **2015**, *5*, 35746-35752. c) G. Sabitha.; A. Raju.; C. N. Reddy.; J. S. Yadav. *RSC Adv* **2014**, *4*, 1496-1502. d) G. Sabitha.; A. S. Rao.; A. Sandeep.; J. S. Yadav. *Eur. J. Org. Chem.* **2014**, 455-465. e) G. Sabitha.; K. Shankaraiah.; J. S. Yadav. *Eur. J. Org. Chem.* **2013**, 4870-4878. f) G. Sabitha.; A. S. Rao.; J. S. Yadav. *Tetrahedron: Asymmetry* **2011**, *22*, 866-871. g) G. Sabitha.; C. N. Reddy.; P. Gopal.; J. S. Yadav. *Tetrahedron Lett.* **2010**, *51*, 5736-5739. h) G. Sabitha.; S. S. S. Reddy.; J. S. Yadav. *Tetrahedron Lett.* **2010**, *51*, 6259-6261. i) G. Sabitha.; S. S. S. Reddy.; J. S. Yadav. *Tetrahedron Lett.* **2011**, *52*, 2407-2409.
17. A. Carpita.; S. Braconi.; R. Rossi. *Tetrahedron: Asymmetry* **2005**, *16*, 2501-2508. b) Y. Zhang.; L. Deng.; G. Zhao. *Org. Biomol. Chem.* **2011**, *9*, 4518-4526.
18. a) T. Katsuki and K. B. Sharpless. *J. Am. Chem. Soc.*, 1980, **102**, 5974-5976. b) Y. Gao.; R. M. Hanson.; J. M. Klunder.; S. Y. Ko.; H. Masamune.; K. B. Sharpless. *J. Am. Chem. Soc.* **1987**, *109*, 5765-5780.
19. A. V. R. Rao.; E. R. Reddy.; B. V. Joshi and J. S. Yadav. *Tetrahedron Lett.*, 1987, **28**, 6497-6500.
20. W Yu.; Y Mei Y.; Y Kang.; Z Hua and Z Jin. *Org. Lett.* **2004**, *6*, 3217-3219.
21. G. Sabitha.; S. K. Das.; P. AnkiReddy.; J. S. Yadav. *Tetrahedron Lett.* **2013**, *54*, 1097-1099.
22. The diastereomeric ratio of the product was determined using a Shimadzu high-performance liquid-chromatography (HPLC) system equipped with a chiral HPLC column (Chiralcel OD) and a UV detector at an absorbance of 225 nm. ATLANTIS C18 150 x 4.6 mm, 5 μ (column) and a solvent system of acetonitrile and water (7:3) at a flow rate of 1.0 ml/min were used. t_R : 6.5 and 6.7 min.
23. a) I. Ohtani.; J. Kusumi.; Y. Kashman.; H. Kakisawa. *J. Am. Chem. Soc.* **1991**, *113*, 4092-4096; For determination of the absolute stereochemistry of secondary/secondary diols by modified Mosher's method, see: b) F. Freire.; J. M. Seco.; E. Quiñoá.; R. Riguera. *J. Org. Chem.* **2005**, *70*, 3778-3790. c) W. Y. Yoshido.; P. J. Bryan.; B. J. Baker.; J. B. McClintock. *J. Org. Chem.* **1995**, *60*, 780-782.
24. a) M. T. Crimmins.; K. Chaudhary. *Org. Lett.* **2000**, *2*, 775-777. b) M. B. Hodge.; H. F. Olivo. *Tetrahedron* **2004**, *60*, 9397-9403. c) M. T. Crimmin.; B. W. King.; E. A. Tabet.; K. Chaudhary. *J. Org. Chem.* **2001**, *66*, 894-902.
25. H. Hori.; Y. Nishida.; H. Ohru. *J. Org. Chem.* **1989**, *54*, 1346-1353.

Graphical Abstract

